Jose Maria Sanchez-Diaz
Overview
Explore the profile of Jose Maria Sanchez-Diaz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Otero R, Solier-Lopez A, Sanchez-Lopez V, Oto J, Arellano E, Marin S, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681751
The most appropriate duration of anticoagulant treatment for cancer-associated venous thromboembolism (CAT) remains unclear. We have conducted a prospective multicenter study in CAT patients with more than 6 months of...
2.
Barca-Hernando M, Munoz-Martin A, Rios-Herranz E, Garcia-Escobar I, Beato C, Font C, et al.
Cancers (Basel)
. 2021 Jun;
13(11).
PMID: 34063886
Anemia is a common condition in cancer patients and is associated with a wide variety of symptoms that impair quality of life (QoL). However, exactly how anemia affects QoL in...
3.
Barca-Hernando M, Ortega-Rivera R, Lopez-Ruz S, Elias-Hernandez T, Asensio-Cruz M, Marin-Romero S, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32823554
In symptomatic acute pulmonary embolism (PE), the presence of deep vein thrombosis (DVT) is a risk factor for 30- and 90-day mortality. In patients with cancer and incidental PE, the...
4.
Marin-Romero S, Elias-Hernandez T, Asensio-Cruz M, Ortega-Rivera R, Morillo-Guerrero R, Toral J, et al.
Arch Bronconeumol (Engl Ed)
. 2019 May;
55(12):619-626.
PMID: 31130245
Introduction: Scales for predicting venous thromboembolism (VTE) recurrence are useful for deciding the duration of the anticoagulant treatment. Although there are several scales, the most appropriate for our setting has...
5.
Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M, Blasco-Esquivias I, Sanchez-Lopez V, et al.
Br J Cancer
. 2018 Oct;
119(8):915-921.
PMID: 30318508
Background: Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity C-reactive protein (hs-CRP) levels after the withdrawal of anticoagulation treatment to predict...
6.
Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M, Blasco-Esquivias I, Marin-Barrera L, et al.
Thromb Res
. 2017 Jul;
157:90-96.
PMID: 28719850
Introduction: The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6months are unknown. Our aim was to determine the safety of long-term tinzaparin...
7.
Jara-Palomares L, Marin-Barrera L, Giraldez-Gallego A, Garzon-Benavides M, Elias-Hernandez T, Praena-Fernandez J, et al.
Thromb Res
. 2017 Apr;
154:55-58.
PMID: 28414933
No abstract available.